LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-Small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer - Contacts and Locations

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-Small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

This study has been completed.
Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005858

Locations


United States, Maryland
	Marlene and Stewart Greenebaum Cancer Center, University of Maryland
	Baltimore, Maryland, United States, 21201
	Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
	Bethesda, Maryland, United States, 20892-1182

Sponsors and Collaborators

University of Maryland Greenebaum Cancer Center

National Cancer Institute (NCI)

Investigators


Study Chair:	Judith E. Karp, MD	Sidney Kimmel Comprehensive Cancer Center